Lifecore Biomedical, Inc.
LFCR
$6.38
$0.213.40%
NASDAQ
| 02/23/2025 | 11/24/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 7.95% | 31.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.95% | 31.81% | |||
| Cost of Revenue | 17.83% | 11.19% | |||
| Gross Profit | -11.18% | 105.75% | |||
| SG&A Expenses | -5.80% | -12.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.75% | 0.98% | |||
| Operating Income | -47.46% | 82.88% | |||
| Income Before Tax | -126.36% | 59.84% | |||
| Income Tax Expenses | -118.60% | 272.00% | |||
| Earnings from Continuing Operations | -124.76% | 59.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -124.76% | 59.51% | |||
| EBIT | -47.46% | 82.88% | |||
| EBITDA | -144.38% | 106.90% | |||
| EPS Basic | -85.31% | 51.84% | |||
| Normalized Basic EPS | -21.90% | 60.01% | |||
| EPS Diluted | -85.55% | 52.21% | |||
| Normalized Diluted EPS | -21.90% | 60.01% | |||
| Average Basic Shares Outstanding | 7.74% | 11.36% | |||
| Average Diluted Shares Outstanding | 7.74% | 11.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||